Alzheimer's Rollercoaster: Azeliragon Misses Endpoints, But Responding Subgroup Identified
US biotech vTv Therapeutics has again reported disappointing top-line Phase III clinical study results for its potential Alzheimer's disease therapy, azeliragon, but believes it has identified a possible path to continued development.
You may also be interested in...
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.
Just weeks after Johnson & Johnson halted development of its BACE inhibitor for Alzheimer's and a few months after Merck & Co failed at Phase III, Lilly and AstraZeneca end trials of lanabecestat.